Monday, September 18, 2023 Daily Archives

The Powers of Odin: Comprehensive Cellular Characterization

Prokaryotic and eukaryotic cells change and adapt to their environments in ways that genomic characterization methods do not fully capture or predict. Even strains of the same species of microbe can show key differences in pathogenicity or sensitivity. Phenotypic analysis provides a complementary method for effectively characterizing the functional properties of cells. Biolog Phenotype MicroArray panels with redox reporter dyes have made this type of analysis possible for many years, as researchers grow their organisms under thousands of different pre-selected…

CancerVax teams with UCLA to develop universal CAR-T platform

CancerVAX will adapt the technology developed for its universal cancer project to create a universal CAR-T platform with the UCLA. CancerVAX, a pre-clinical biotechnology firm working with a research team from the University of California, Los Angeles (UCLA), has expanded its development pipeline to include a universal chimeric antigen receptor (CAR) T-cell platform. Following a recent meeting between company executives and the UCLA research team, CancerVAX said its nanoparticle technology developed for the current universal cancer vaccine project, can be…

BWB 2023: Timelines, tech, trust critical to CDMO management success

Not respecting timelines and a reliance on proprietary technologies are among the warning signs a developer must be aware of when selecting a CDMO, says a biopharma consultant. James Blackwell, president and principal consultant at The Windshire Group, spoke to a procurement-focused audience at Biotech Week Boston (BWB) today about the best practices when working with a contract development and manufacturing organization (CDMO). The decision of “whether to make or buy” has long been discussed, and as most biotechs do…

Samsung Biologics invests and partners with Korean ADC firm

Samsung Bio has inked an ADC development pact with AimedBio after investment wing Samsung Venture Investment Corporation took a stake in the company. The undisclosed investment was made by Samsung Life Science Fund, a joint creation between Samsung Biologics, Samsung C&T, and Samsung Bioepis, which is managed by Samsung Ventures Investment Corporation (Samsung Ventures), an investment corporation that aims to promote the advancement of technologies. A spokesperson from Samsung Bioepis told BioProcess Insider the total value of the Samsung Life…

Loss of confidence? Another Lonza CEO unexpectedly leaves

The unexpected departure of Lonza CEO Pierre-Alain Ruffieux is most likely the Board’s loss of confidence in his execution, according to an analyst. Swiss contract development and manufacturing organization (CDMO) Lonza announced this morning it is to part ways with Ruffieux by mutual agreement at the end of the month. Ruffieux joined Lonza from Roche, taking the top job in November 2020. No reason was given but Jefferies’ analyst Peter Welford noted “the decision to seek a new CEO may…

Imugene gains FDA tick for allogeneic CAR-T manufacturing changes

The US FDA has approved changes in the manufacturing process for azer-cel, an allogeneic (off the shelf) CAR-T recently added to Imugene’s pipeline. Azercabtagene zapreleucel (azer-cel) is an anti-CD19 allogeneic CAR T candidate being studied in an ongoing multi-centre Phase Ib clinical trial in patients with non-Hodgkin’s lymphoma (NHL) and acute lymphocytic leukemia (ALL). Leslie Chong, CEO of the Australian immuno-oncology company Imugene, said: “Azer-cel has the potential to be the first CD19 directed allogeneic cell therapy and having the…